🛡️ LRCX $21M Put Block — Semicap Factor Hedge on a +282% YTD Rocket

📅 May 28, 2026 | 🤝 Block Cross Detected

✅ Last updated: 2026-05-29 — open/close confirmed by next-day OPRA OI (see OI UPDATE below).

---

🎯 The Quick Take

A desk just crossed $21 million in downside protection on Lam Research — 7,500 put contracts struck ≈9% below spot, expiring August 21, 2026, with earnings on ≈August 5 sitting directly inside the window. This is a negotiated institutional block, not a lit-market panic sweep: a known counterparty agreed to the other side of this trade off the open order book. Now combine this with an identical $21M put block on KLAC the same morning and you have your answer: this is not a single-name bet. A desk is hedging the entire semicap equipment factor — both best-performing names, same day, same premium, same expiry. At +282% YTD and ≈60x trailing earnings, LRCX is a very logical name to buy a seatbelt on.

---

📊 Company Overview

Lam Research Corporation (NASDAQ: LRCX) is where the wafers actually get built:

• What it does: Etch and deposition equipment — the tools that carve circuit patterns into silicon and layer materials onto wafers. Nearly every NAND flash chip, DRAM module, and advanced logic device in the world passes through Lam's chambers at some point.
• Why AI loves it: HBM memory (the high-bandwidth stack inside every Nvidia H100/H200/B200) requires Lam's equipment at dozens of steps per wafer. As AI drives memory capex into record territory, Lam's tool orders follow.
• Market Cap: ≈$401 billion
• Sector: Semiconductor Capital Equipment (Etch & Deposition)
• China exposure: Highest among the big-three semicap peers — the most China-sensitive name in the group, which is both a growth lever and a risk lever.

Current Price: ≈$319 | +282% YTD 2026 | Near all-time high of $333.33

Note: LRCX completed a 10-for-1 stock split in October 2025. All prices and strikes in this article reflect post-split figures.

---

💰 The Option Flow Breakdown

📊 The Tape — May 28, 2026 @ 10:06:32 ET

Flow Type: 🤝 BLOCK CROSS — single-leg negotiated block. Buyer and seller agreed on price through a facilitating broker. Not an exchange sweep.

Order Classification: BTO (Buy to Open) — the classifier assessed this as a fresh opening position based on today's volume (7,500) against existing OI (15,000), where Vol/OI = 0.5. This is consistent with a new opening. ⏳ Next-day OI confirmation at ≈06:30 ET is the definitive test — if OI rises by ≈7,500, this was definitively BTO. We'll flag the update when OI data is available. No prior position found in our 180-day archive.

✅ OI UPDATE (2026-05-29): OPEN CONFIRMED. The next-day OPRA open-interest snapshot (reflecting 2026-05-28 EOD) shows the $290 put open interest rose from 15,264 to 22,801 (Δ +7,537), ≈ the 7,500-contract trade — confirming this was a genuine opening position (BTO), not a close (STC). Because Vol (7,500) was below prior OI (15,264), open-vs-close could not be proven from the tape alone — the OI rise of ≈+7,500 is the definitive test, and it landed squarely on the open side. The semicap-factor-hedge read above holds.

🤓 What This Actually Means

Let's break this down in plain English.

The LRCX put printed 28 minutes before the KLAC put. Both are:

• Block crosses (single-leg, negotiated, known counterparty on the other side)
• $21M premium
• August 21, 2026 expiry
• 9-11% out-of-the-money
• Covering a near-term earnings binary

That is not a coincidence. That is a coordinated semicap-factor hedge.

Here's the logic: if you manage a fund that has made enormous money on the AI-driven WFE supercycle — owning LRCX up 282%, KLAC up 154% — you face a common portfolio problem: the positions are enormous relative to your cost basis, and a single bad earnings call (LRCX reports ≈August 5, KLAC ≈July 30) could wipe out months of gains in a day. Selling would trigger taxes and close winning positions. Buying puts on both simultaneously for $42M total is the elegant solution — you keep all the upside, you cap the catastrophic downside, and both positions expire by August 21.

• 💸 $21M in premium buys protection on 750,000 shares worth ≈$239M at today's price.
• 🛡️ Strike at $290 = ≈9% below spot. LRCX has to fall through $290 for the put to earn profit net of premium.
• 📅 August 5 earnings inside the August 21 expiry — the put is specifically constructed to capture the post-earnings move plus two weeks of follow-through. That is textbook event-risk hedging.

The most honest framing: a put buy does not prove a directional short. It is equally consistent with protecting a large long. The coordinated KLAC twin strengthens the "semicap-factor hedge on long positions" read significantly.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

The LRCX chart is extraordinary. Stockanalysis.com shows +281.8% YTD and +248% over the trailing 52 weeks — a move that has essentially tripled the stock in a year. The all-time high close was $322.68 on May 26, 2026 — literally two days ago. The stock is trading within ≈4% of its record peak.

That is the setup that creates demand for downside insurance. You don't hedge a position that's flat. You hedge one that's tripled.

Gamma-Based Support & Resistance

The gamma exposure map for LRCX shows a tight, well-defined range around the current price, with the put-heavy $290 strike standing out clearly in the data:

🔵 Support Level (Put Gamma — dealer-bid zone):

• $310 — Nearest support, ≈3.5% below spot. Net GEX ≈+1.94 (call-heavy, moderate strength). Dealer buying here supports the stock on shallow dips. A break below $310 removes a key near-term floor.
• $290 — This is where the action is. Net put GEX ≈-1.54 — the single most put-heavy strike on the board, with total GEX of ≈2.71. This is the strike where 7,500 contracts just printed. The concentration of put open interest here creates a gravitational pull: if LRCX approaches $290 into August 5 earnings, dealer hedging flows amplify the move.
• $280 — Secondary support, net GEX ≈+0.24. A meaningful gamma floor if $290 breaks.

🟠 Resistance Levels (Call Gamma — dealer-sell zone):

• $330 — Immediate overhead resistance, ≈2.7% above spot. Net call GEX ≈+2.52 (moderate strength). The stock's all-time high ($333.33) sits just above this level, reinforcing the technical ceiling.
• $340 — Stronger resistance, net call GEX ≈+3.33 (the single largest call-GEX level). For LRCX to break through $340 and sustain a new high, it would need a blowout earnings beat plus strong FY2027 WFE guidance.

Key takeaway: LRCX is sandwiched between the $310 support floor and the $330 ceiling — a ≈$20 range in a ≈$319 stock. The $290 put concentration creates a "trap door" if sentiment shifts: approaching that level would trigger additional dealer hedging, amplifying any downside move. That is exactly why 7,500 contracts there is a meaningful hedge, not just a directional bet.

Implied Move Analysis

What are options traders pricing for each expiration?

• 📅 Tomorrow May 29 (1 day): ±$13 (±4.1%) → Range: $307 – $334
• 📅 July 17 OPEX (50 days): ±$80 (±24.8%) → Range: $241 – $400
• 📅 August 21 OPEX — THIS TRADE: Market pricing upper ≈$426, lower ≈$215
• 📅 September 18 Triple Witch (113 days): ±$120 (±37.5%) → Range: $201 – $441

Translation: by the August 21 expiry, the options market is pricing a potential lower range all the way to ≈$215. The $290 strike sits solidly inside the lower implied range. The options market is not calling $290 a fantasy — it's pricing meaningful probability of the stock trading there or below over the next 85 days, particularly given the August 5 earnings binary.

The ±24.8% July OPEX implied move also tells you something important: options on LRCX are expensive right now. High IV means option premiums are elevated, which means the put buyer paid up — $28.50 per contract — and accepted that cost as the price of insurance on a tripled position.

---

🎪 Catalysts

🔥 Key Upcoming Event — August 5, 2026 Earnings (INSIDE THE PUT WINDOW)

Q4 FY2026 (June-quarter) earnings are expected on or about August 5, 2026 — approximately two weeks before the August 21 put expiry. The company has already guided:

• Revenue: $6.6B ± $400M — a record
• Non-GAAP EPS: $1.65 ± $0.15 — a record
• Gross Margin: 50.5% ± 1ppt

What the bears need: A cautious FY2027 WFE framework — "we see equipment spend plateauing after 2027" — combined with China revenue falling faster than the guided <30%, or NAND conversion delays. Seeking Alpha has explicitly flagged "frothy levels" as a concern heading into the print.

What the bulls need: Revenue toward the top of the $6.6B ± $400M guide, an affirmative stance on Morgan Stanley's $149B WFE bull case for 2026, and confidence in NAND conversion pull-forward through 2027.

✅ Recent Results (Already Happened)

• Q3 FY2026 (April 22, 2026): Revenue $5.84B (+24% YoY), non-GAAP EPS $1.47 — beat consensus by ≈8%. First-ever Customer Support Business Group (CSBG) quarter above $2B. 2026 WFE forecast raised to $140B.
• NAND conversion pull-forward: $40B in NAND upgrades now expected before end of 2027 — a major near-term demand signal for Lam's etch franchise.
• DRAM 1C-node SAM: Projected to grow >20% as chipmakers transition to advanced DRAM nodes — direct leverage to HBM and DDR5.

📅 Other Catalysts to Watch

• China / Export Controls: LRCX has the highest China revenue concentration among the big-three semicap peers. China was 34% of revenue in Q3 FY2026 and is guided to fall below 30% by end-2026. The "50% affiliate rule" alone is expected to cut ≈$600M from 2026 revenue. Any further U.S.-China export tightening is an unscheduled downside catalyst.
• Morgan Stanley Upgrade (Recent, Bullish Signal): In a notable May 18 call, MS upgraded LRCX to Overweight from Equal-weight with a $331 PT, citing NAND WFE as the fastest-growing end market in 2027. MS's bull case is $436. Mizuho also raised to $380 from $330.
• HBM Memory Ramps: SK Hynix, Samsung, and Micron are collectively spending >$60B annually on capacity expansion — each wafer start needs Lam's tools at multiple steps.
• 2027 WFE Cycle Debate: Morningstar has flagged LRCX as "overvalued" post-rally. The disconnect between MS's $149B WFE bull case and more conservative $126-135B estimates means the August 5 FY2027 commentary is a genuine binary swing factor.

---

🎲 Price Targets & Probabilities

📈 Bull Case (30% probability)

Target: $330 – $370

LRCX breaks through the $330 call-gamma ceiling on a record beat: revenue above $7B (top of guide), a confident FY2027 WFE tone, and strong NAND conversion commentary. Morgan Stanley's $331 base case and Mizuho's $380 bracket the bull range. The $290 put expires worthless, and the ≈$21M cost is simply the price of keeping the long position hedged through the event.

🎯 Base Case (45% probability)

Target: $295 – $330 (range-bound)

In-line earnings, solid but unsurprising FY2027 WFE guidance, no China shock. LRCX chops between the $310 gamma support and $330 overhead resistance. The put decays — the insurance wasn't needed, which is fine. This is the most common outcome after options-heavy earnings setups.

📉 Bear Case (25% probability)

Target: $260 – $295 (stress the hedge)

A cautious FY2027 WFE guide or an unexpected China export tightening. LRCX breaks the $310 gamma support and approaches the $290 put strike. At $290, the trade turns neutral (put is at-the-money, recovering the premium paid). Below $290, the put earns profit dollar-for-dollar.

Put P&L at various LRCX prices on August 21:

• LRCX at $290: put at-the-money, ≈full premium recovery
• LRCX at $270: put worth ≈$20, gain ≈-$8.50/contract × 7,500 = -$6.4M (partial loss, but hedged the long)
• LRCX at $250: put worth ≈$40, net gain ≈+$11.50/contract × 7,500 = +$8.6M
• LRCX above $290: put expires worthless, loss = $21M (the insurance premium)

---

💡 Trading Ideas

🛡️ Conservative: Let the Earnings Binary Clear

The play: Don't fight the tape into August 5. The options market is pricing ±25% for July OPEX — that's enormous for a large-cap. Wait for the August 5 print, let IV collapse, and then assess whether the FY2027 WFE guide justifies the current 60x trailing multiple.

What to look for on August 5: Revenue above $7B (top of guide), China <30% on track, NAND conversion cadence confirmed through 2027, gross margins holding above 50%. If all four check out, LRCX above $330 is achievable. If any disappoint, the $290-$310 gamma zone becomes the test.

Risk level: Low | Skill level: Beginner-friendly

⚖️ Balanced: Post-Earnings Bear Put Spread

The play: If August 5 earnings tone is cautious — FY2027 WFE guidance below $140B, or China revenue falling faster than guided — buy a $310/$290 put spread for September expiry after IV crush.

Economics (estimated post-earnings): Net debit ≈$8-12 per spread after IV crush, max profit ≈$20 if LRCX below $290 at September expiry. Risk/reward approaching 2:1 with defined maximum loss.

Why this works: You're targeting the exact gamma corridor the data highlights — $310 support break leading to $290 put concentration zone. You buy after earnings when options are cheaper, not before when they're expensive.

Risk level: Moderate | Skill level: Intermediate

🚀 Aggressive: Pre-Earnings Strangle

The play: Buy the $340 call and the $290 put, both August 21, before August 5 earnings. You're betting the realized move exceeds the implied move in either direction.

Why this could work: Morgan Stanley's bull case is $436, implying a 37% upside scenario. The bear case from Morningstar's "overvalued" call implies meaningful downside. If the realized move is truly extreme, a strangle captures it regardless of direction.

Why this could blow up: Pre-earnings IV is already elevated on LRCX. After the August 5 print, IV collapses and both legs lose value simultaneously unless the stock actually moves far enough. This is an "outsized move" bet, not a direction bet. Most earnings don't deliver outsized moves.

Risk level: High | Skill level: Advanced only

---

👥 4 Trader Types: What This Means for You

🎰 YOLO Trader: The whale picked $290 because it's ≈9% OTM and covered by a gamma wall. If you want a more aggressive strike, the $300 puts for August 21 are closer to at-the-money and cheaper on a net basis. Be warned: you're paying elevated implied vol for a put that needs a genuine August 5 earnings miss to pay off. If Lam blows out the guide, you lose the full premium.

📊 Swing Trader: The gamma map is your playbook. The range is roughly $310 (support, with the $290 put wall below) to $330 (immediate resistance) to $340 (bigger resistance). Buy near $310 on weakness ahead of earnings, target $330. If earnings break $330, pyramid up. If earnings break $310, step aside and let the gamma pressure run to $290.

💰 Premium Collector: The $290 put is a significant put-gamma anchor. If you believe LRCX holds above $290 through August 21, selling the $270/$290 put spread collects premium in the ≈9-11% OTM zone with defined max loss of $20 per spread. Just be aware: an earnings miss on August 5 can gap right through your short strike. Never sell naked puts into a known earnings binary without clearly defined risk.

🐣 Entry Level — The Beginner Lesson: You just watched a desk spend $21M on LRCX puts on the same day they spent $21M on KLAC puts. Here is the single most important thing to understand: a put buy does not mean the buyer expects the stock to crash. More often than not, it means they already own a ton of the stock and want insurance. Think of it like buying travel insurance before a vacation — buying it doesn't mean you expect your trip to be ruined. It means the trip is important enough to protect. When stocks are up 282% in a year, smart money buys protection. That's not fear — it's professionalism.

---

⚠️ Risk Factors

• ❗ Valuation at ≈60x trailing earnings after a +282% year. Seeking Alpha has explicitly called Lam "approaching frothy levels". At this multiple, "in line" earnings can still be a disappointment if guidance doesn't accelerate the narrative.
• ❗ China exposure is the highest in the peer group. China was 34% of revenue in Q3 FY2026, being guided to <30% — the ≈$600M 2026 revenue headwind from the 50% affiliate rule is already modeled in. Any incremental BIS tightening is an additional unscheduled hit.
• ❗ WFE cycle debate is not resolved. The Street is split between Lam's own $140B forecast, Morgan Stanley's $149B bull case, and more conservative $126-135B estimates. The August 5 FY2027 commentary is the next data point. A "plateau" guide would crack the thesis.
• ❗ NAND conversion timing risk. The bull thesis requires $40B in NAND upgrades to happen before end of 2027. Any delay in that pull-forward removes the near-term demand catalyst.
• ❗ The coordinated twin — KLAC — adds weight to the hedge read. A fund that bought puts on both names the same morning is telling you: "I'm uncertain enough about the semicap cycle to pay $42M combined for insurance." That is a sophisticated voice worth listening to, even if it doesn't predict a specific outcome.
• ❗ Put buy confirmation is next-day OI. We are classifying this BTO as a fresh open, consistent with the classifier output. However, no prior position was found in the archive or 180-day OI history, so there is a small possibility this is closing an existing short (STC). ⏳ If OI rises by ≈7,500 contracts the next morning, the BTO read is confirmed.

---

🎯 The Bottom Line

Real talk: Someone bought $21M of Lam Research puts and $21M of KLAC puts on the same morning, same expiry, both covering earnings binaries. This is not two traders with the same idea — this is one coordinated decision to hedge the semicap factor heading into the most important earnings season for the AI-capex narrative.

Lam Research is a genuinely excellent business. Record revenue at $5.84B, record guidance at $6.6B, a recurring services segment that just crossed $2B for the first time, Morgan Stanley calling it the top semicap pick for 2027 NAND. The fundamental story is intact.

The issue is price. Up 282% YTD at ≈60x earnings, within 4% of the all-time high, with Morningstar already flagging it as overvalued — the stock is priced for flawless execution. August 5 earnings will tell us whether the WFE cycle is accelerating into 2027 or plateauing. That single question is worth $21M of insurance to the desk that bought these puts.

If you own LRCX: You've made extraordinary money. Consider protecting a portion of those gains — the same logic the smart money used to justify this hedge applies to any concentrated long position. Even a 10-15% hedge goes a long way when you're sitting on 282% gains.

If you're watching: Do not initiate a new long position ahead of August 5 into elevated implied vol. Post-earnings is the better entry — let the dust settle, let IV collapse, let the FY2027 guidance reset expectations one way or another.

Mark your calendar:

• 📅 August 5, 2026 (approx.) — Q4 FY2026 earnings (the critical binary for this hedge)
• 📅 August 21, 2026 — Put expiration
• 📅 Ongoing — China/BIS export-control headlines (live, unscheduled risk)

Disclaimer: Options trading involves substantial risk and is not suitable for all investors. This analysis is for educational and informational purposes only and does not constitute financial advice. Past performance does not guarantee future results. The BTO classification is based on the classifier's assessment and is subject to next-day OI confirmation — ⏳ provisional until the June 16 morning OI snapshot. The block-cross flow reflects one negotiated trade; it does not guarantee a specific market direction. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

---

About Lam Research Corporation: Lam Research designs and manufactures semiconductor etch and deposition equipment for the global semiconductor industry. Its tools are critical at dozens of steps in the manufacture of NAND flash, DRAM, and advanced logic devices. Market cap ≈$401 billion, following a 10-for-1 stock split in October 2025.